TY - JOUR
T1 - Author Correction: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity (Nature Communications, (2016), 7, 1, (10787), 10.1038/ncomms10787)
T2 - Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity
AU - Sant’Anna, Ricardo
AU - Gallego, Pablo
AU - Robinson, Lei Z.
AU - Pereira-Henriques, Alda
AU - Ferreira, Nelson
AU - Pinheiro, Francisca
AU - Esperante, Sebastian
AU - Pallares, Irantzu
AU - Huertas, Oscar
AU - Almeida, Maria Rosário
AU - Reixach, Natàlia
AU - Insa, Raul
AU - Velazquez-Campoy, Adrian
AU - Reverter, David
AU - Reig, Núria
AU - Ventura, Salvador
N1 - Publisher Copyright:
© 2023 The Author(s).
PY - 2023/2/3
Y1 - 2023/2/3
N2 - The original version of this Article contained the following errors: The original version of this Article contained an error in the legend of Fig. 5c, which incorrectly omitted the following: ‘Please note that the same control was published in a previous article65 that reported the results obtained for other inhibitors of L55P-TTR aggregation that were tested in the same dot blot assay.’ This error has been corrected in both the PDF and HTML versions of the Article. The original version of this Article omitted a reference to previouswork in ‘Ferreira,N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014)’. This has been added as reference 65 in the legend of Fig. 5c, as described above. This error has been corrected in both the PDF and HTML versions of the Article. In addition, the original version of the Supplementary Information associated with this Article contained errors in Supplementary Fig. 8,which showed an incomplete dot blot andwas accompanied by an incomplete legend, which incorrectly read ‘Selected images of the dot blot used in main figure 5c.’ The correct version of the legend states ‘Uncropped blot for results shown in Figure 5c. Several compounds (including tolcapone, tafamidis, EGCGand CLR01)were tested in the same dot blot assay as potential inhibitors of L55P-TTR aggregation, sharing the same controls (no inhibitor) on an acetate cellulose membrane. Figure 5c showed the results obtained for the control, tolcapone and tafamidis, while a previous article showed the results obtained for the control, CLR01 and EGCG: Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014).’ The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version of Supplementary Fig. 8 can be found as Supplementary Information associated with this Correction.
AB - The original version of this Article contained the following errors: The original version of this Article contained an error in the legend of Fig. 5c, which incorrectly omitted the following: ‘Please note that the same control was published in a previous article65 that reported the results obtained for other inhibitors of L55P-TTR aggregation that were tested in the same dot blot assay.’ This error has been corrected in both the PDF and HTML versions of the Article. The original version of this Article omitted a reference to previouswork in ‘Ferreira,N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014)’. This has been added as reference 65 in the legend of Fig. 5c, as described above. This error has been corrected in both the PDF and HTML versions of the Article. In addition, the original version of the Supplementary Information associated with this Article contained errors in Supplementary Fig. 8,which showed an incomplete dot blot andwas accompanied by an incomplete legend, which incorrectly read ‘Selected images of the dot blot used in main figure 5c.’ The correct version of the legend states ‘Uncropped blot for results shown in Figure 5c. Several compounds (including tolcapone, tafamidis, EGCGand CLR01)were tested in the same dot blot assay as potential inhibitors of L55P-TTR aggregation, sharing the same controls (no inhibitor) on an acetate cellulose membrane. Figure 5c showed the results obtained for the control, tolcapone and tafamidis, while a previous article showed the results obtained for the control, CLR01 and EGCG: Ferreira, N. et al. Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics 11, 450–461 (2014).’ The HTML has been updated to include a corrected version of the Supplementary Information; the original incorrect version of Supplementary Fig. 8 can be found as Supplementary Information associated with this Correction.
UR - http://www.scopus.com/inward/record.url?scp=85147332335&partnerID=8YFLogxK
U2 - 10.1038/s41467-023-36239-z
DO - 10.1038/s41467-023-36239-z
M3 - Article
C2 - 36737445
AN - SCOPUS:85147332335
SN - 2041-1723
VL - 14
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 582
ER -